DexCom, Inc. (DXCM)

Market Cap	27.29B -19.8%
Revenue (ttm)	4.52B +14.2%
Net Income	720.70M +5.9%
EPS	1.80 +7.8%
Shares Out	390.02M
PE Ratio	38.94
Forward PE	29.05
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,659,589
Open	70.57
Previous Close	69.89
Day's Range	68.68 - 70.68
52-Week Range	54.11 - 93.25
Beta	1.49
Analysts	Strong Buy
Price Target	85.05 (+21.55%)
Earnings Date	Feb 12, 2026

About DXCM

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Apr 14, 2005
• Employees: 10,300
• Stock Exchange: NASDAQ
• Ticker Symbol: DXCM
• Website: https://www.dexcom.com

Financial Performance

In 2024, DexCom's revenue was $4.03 billion, an increase of 11.34% compared to the previous year's $3.62 billion. Earnings were $576.20 million, an increase of 6.41%.

Analyst Summary

According to 21 analysts, the average rating for DXCM stock is "Strong Buy." The 12-month stock price target is $85.05, which is an increase of 21.55% from the latest price.

Price Target

$85.05

(21.55% upside)

Analyst Consensus: Strong Buy